纤溶酶原激活系统与肿瘤转移被引量：3

下载PDF

导出

摘要纤溶酶原活化剂 (PlasminogenActivator,PA)分为尿激酶型 (Urokinase ,uPA)和组织型 (TissuePA ,tPA)两种 ,二者水解纤溶酶原转变为纤溶酶 (plasmin) ,纤溶酶使纤维蛋白 (原 )降解。许多实验证明恶性肿瘤细胞具有浸润或转移的特征 ,其纤溶酶及活化剂的表达都较高 ,通过抑制肿瘤细胞纤溶酶原激活系统 ,可以降低肿瘤细胞的转移特征 ,为恶性肿瘤治疗开辟了一条新途径。测定肿瘤患者血浆tPA、uPA的含量 ,对于判断肿瘤是否转移、临床分期和预后 ,可能有着重要价值。

作者杨桂斌沈孟贤

机构地区安徽省阜阳市人民医院血研所

出处《国外医学（临床生物化学与检验学分册）》 2002年第3期141-141,175,共2页 Foreign Medical Sciences(section of Clinical Biochemistry and Laboratory Medicine

关键词纤溶酶原活化剂 TPA UPA 纤溶酶恶性肿瘤转移

分类号 R730.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献16

1Festuccia C, Dolo V, Gueerra F, et al. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells [J].Clin Exp Metastasis, 1998,16 (6): 513-528.
2McWilliam N, Robbie L, Booth N, et al. Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow[J].Br J Haematol, 1998, 101 (4): 626-631.
3肖继平,张广德,夏文华,郭广松,凌长明.乳腺癌中尿激酶型纤溶酶原激活物的过度表达[J].实用癌症杂志,1999,14(4):261-262. 被引量：2
4步星耀,章翔,陈恩志,刘先珍,梁景文,易声禹.尿激酶型纤溶酶原激活因子基因与胶质瘤的侵袭及预后的关系[J].肿瘤,1999,19(4):223-225. 被引量：3
5Cao Y, Veitonmaki N, Keough K, et al. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients[J]. Int J Mol Med, 2000, 5(5) :547-551.
6Brunner G, Reimbold K, Meissauer A, et al. Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation[J]. Exp Cell Res,1998,239(2):301-310.
7Protiva P, Sordat Ⅰ , Chaubert P, et al. Alterations in plasminogen activation correlate with epithelical cell dysplasia grading in colorectal adenomas[J]. Br J Cancer, 1998, 77 (2): 297-304.
8Farina AR, Coppa A, Tiberio A, et al. Transforming growth factor-betal enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity [J].Int J Cancer,1998,75(5) :721-730.
9Kobayashi H, Gugino D, She MY, et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain Ⅱ of bikunin efficiently inhibits tumor cell invasion and metastasis[J]. Eur J Biochem, 1998,253(3) :817-826.
10Durko M, Brodt P. Suppression of type Ⅰ collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinasetype plasminogen activator receptor[J]. Biochem Biophys Res Commun,1998,247(2) :342-348.

二级参考文献10

1步星耀金百祥等.nm23-H1 mRNA表达与肾母细胞瘤临床行为的关系[J].中国肿瘤临床,1997,24:179-179.
2Chen Z Q，Cancer，1997年，57卷，20页
3步星耀，中国肿瘤临床，1997年，24卷，179页
4Maeda K，Br J Cancer，1995年，72卷，319页
5Yu H，Cancer Res，1990年，50卷，7623页
6Duggan C, Maguire T, Mcdermott E,et al.Urokinaseplasminogen activator and urokinase plasminogen activator receptor in breast cancer Int JCancer 1995,61∶597-600.
7Mayerhofer K, Stolzlechner J, Yildiz S, et al. Plasminogen activator inhibitor 1and prognosis in breast carcinoma.Geburtshilfe Frauenheilkd,1996,56∶23-27.
8Stefansson S, Kounnas MZ, Henkin J,et al,Gp 330 on type Ⅱ pneumocytes mediatesendocytosis leading to degradation of prourokinase plasminogcn activator inlibitor-1 andurokinase/plasminogen activator inhibitor-1 complex.J Cell Sci, 1991，108(Pt6)∶2361-2368.
9Schmitt M, Harbeck N, Thomssen C,et al Clinical impact of the plasminogen activation system in tumor invasion and metastasis:prognostic relevance and target for therapy.Thromb Haemost, 1997,78(1)∶285-291. （收稿：1999-12-27　修回:2000-02-11）
10郑起,汤钊猷,吴志全,施达仁,唐辉滨,朱运松,宋后燕.尿激酶型纤溶酶原激活物及其特异受体和抑制物与肝细胞癌浸润转移及预后[J].中华肿瘤杂志,1998,20(1):57-59. 被引量：17

共引文献17

1李劲峰,杨林花.淋巴瘤患者血液纤溶状态的变化及其意义[J].山西医药杂志,2005,34(2):133-134.
2李劲峰.淋巴瘤患者血液t-PA与PAI-1的变化及其意义[J].山西职工医学院学报,2005,15(1):10-13. 被引量：1
3宋保新,郑伟,王运杰,曾昭书.HGF,uPA在脑胶质瘤中的表达及意义[J].中国医科大学学报,2005,34(3):251-252. 被引量：3
4郭云武,徐志,卢兴国,朱蕾,许试文.癌组织浸出液组织型纤溶酶原激活物和凝血酶调节蛋白的初步观察[J].中国微循环,2005,9(3):207-207.
5于庭,王宝才,刘昕鸣.恶性肿瘤患者血浆tPA、uPA检测的临床意义[J].实用全科医学,2005,3(6):490-490. 被引量：1
6唐芙爱,刘霞,刘占举,程香普,郑鹏远,李振峰.大肠癌组织中尿激酶纤溶酶原激活物及微血管密度检测[J].郑州大学学报（医学版）,2006,41(6):1070-1072. 被引量：1
7何芳,朱艳.卵巢癌早期诊断技术的研究进展[J].医学综述,2007,13(12):907-908.
8荆莉玲.纤溶酶原激活剂与抑制剂的测定方法和临床意义[J].现代中西医结合杂志,2007,16(34):5168-5169.
9王丽,宋兰英,刘运江.乳腺癌组织uPA和PAI-1表达与临床病理因素相关性的探讨[J].中华肿瘤防治杂志,2009,16(22):1765-1769. 被引量：7
10陈渝宁,张盈华,张利朝.纤溶酶原激活剂与抑制剂的研究及临床意义[J].临床检验杂志,1999,17(3):189-190. 被引量：6

同被引文献15

1Cheng J,Bierhaus A,Schiekofer S,et al.Tissue factor-a receptor involved in the control of cellular properties,including angiogenesis [J].Thromb Haemost, 2001,86:334-345.
2Donati MB,Lorenzet R.Coagulation factors and tumor cell biology:the role of tissue factor [J].Pathophysiol Haemost Thromb, 2003,33 (Suopl 1 ):22-25.
3Sawada M,Miyake S, Ohdama S,et al. Expression of tissue factor in non-small cell lung cancer and its relationship to metastasis[J].Br J Cancer, 1999,79(3-4):472-477.
4Lykke J, Nielsen HJ.The role of tissue factor in colorectal cancer[J].Eur J Surg Oncol,2003,29(5):417-422.
5Mazar AP,Henkin J,Goldfarb RH.The urokinase plasminogen activator system in cancer:implications for tumor angiogenesis and metastasis [J].Angiogenesis,1999,3(1):15-32.
6Taniguchi T, KakkarAK,Tuddenham EGD,et al. Enhanced expression of urokinase receptor induced through the tissue factor-factor Ⅶ a pathway in human pancreatic cancer[J].Cancer Res, 1998,58(19) :4461-4467.
7Mazar AP,Henkin J,Goldfarb RH.The urokinase plasminogen activator system in cancer:implications for tumor angiogenesis and metastasis. Angiogenesis, 1999,3 ( 1 ): 15-32.
8Reuning U, Magdolen V, Wilhelm O, et al.Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol, 1998,13 (5) :893.
9Cantero D,Friess H,Zimmermann A,et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Can, 1997,75(3) :388.
10Foekens JA,Peters HA,Look MP,et al.The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res, 2000,60(3): 636.